Showing items 1 - 3 of 3

Your selections:

A phase III randomized trial of high-dose CEOP + filgrastim versus standard-dose CEOP in patients with non-Hodgkin lymphoma: 10-year follow-up data: Australasian Leukaemia and Lymphoma Group (ALLG) NHL07 trial

- Hertzberg, Mark, Matthews, Jane Palfrey, Abdi, Ehtesham, Green, Michael, Bonaventura, Anthony, Marlton, Paula, Cannell, Paul, Wolf, Max, Stone, Janey Malka, Dubosq, Ming-Celine, Grigg, Andrew, Ellis, David, Benson, Warwick, Browett, Peter, Horvath, Noemi, Januszewicz, Henry

Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives

- De Boer, Richard, Beith, Jane, Zdenkowski, Nicholas, Bell, Richard, Chirgwin, Jacquie, Chua, Sue, Colosimo, Maree, Francis, Prudence, Green, Michael, Pittman, Ken, White, Michelle, Wilcken, Nicholas

Systemic treatment of HER2-positive metastatic breast cancer: a systematic review

- Wilcken, Nicholas, Zdenkowski, Nicholas, Chua, Sue, Chirgwin, Jacquie, Beith, Jane, Bell, Richard, White, Michelle, Snyder, Ray, Pittman, Ken, Mainwaring, Paul, Green, Michael, Francis, Prudence, De Boer, Richard, Colosimo, Maree

  • 1
  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit